Keynatinib

DRUG2 trials

Sponsors

Medolution Ltd.

Conditions

Brain MetastasesLymphoma, B-CellNon-Small Cell Lung Cancer With EGFR Mutation

Phase 1

Phase Ib Clinical Study of Keynatinib

RecruitingNCT04807881

Medolution Ltd.Lymphoma, B-Cell

Start: 2020-09-24End: 2028-04-10Target: 75Updated: 2025-01-22

Phase 2

Keynatinib in Treated Patients With NSCLC and Brain Metastases

CompletedNCT04824079

Medolution Ltd.Brain Metastases, Non-Small Cell Lung Cancer With EGFR Mutation

Start: 2020-10-21End: 2024-12-10Updated: 2025-01-22